In-hospital SGLT2 inhibitor initiation, prescribing gaps, and 30-day all-cause readmission in heart failure with reduced ejection fraction: a US post-guideline cohort study
Otabek Pulatov, Soo Young Kim, Zvi Grossman, Farhan Noor, Bilal Salam, Tahmid Khan, Akhila Matam, Shan Wang, Thomas Caraccio, Kevin P. Marzo · 2026
Read In-hospital SGLT2 inhibitor initiation, prescribing gaps, and 30-day all-cause readmission in heart failure with reduced ejection fraction: a US post-guideline cohort study by Otabek Pulatov, Soo Young Kim, Zvi Grossman, Farhan Noor, Bilal Salam, Tahmid Khan, Akhila Matam, Shan Wang, Thomas Caraccio, Kevin P. Marzo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13647711.txt.
Introduction
Otabek Pulatov and nine colleagues study whether starting an SGLT2 inhibitor during the hospital stay cuts readmission for heart failure patients, in a 2026 cohort. Guidelines elevated these drugs to top-tier therapy for weakened-heart failure in 2022, yet prescribing lagged. Records covered 438 patients discharged from four NYU Langone hospitals between January 2023 and January 2026. The main analysis focused on 221 patients whose hearts pumped at forty percent or less.
About twenty-eight percent of patients started the drug in hospital, and uptake in the weak-heart group had climbed sixfold since an earlier survey. Those patients returned within thirty days far less often than untreated peers, and the gap survived statistical weighting designed to mimic a trial. One gap stood out: patients with a previous heart failure admission started the drug least often. The authors argue hospitals should close that paradox, since prior admission marks the patients with most to gain.
Catalog record
| CREATOR | Otabek Pulatov, Soo Young Kim, Zvi Grossman, Farhan Noor, Bilal Salam, Tahmid Khan, Akhila Matam, Shan Wang, Thomas Caraccio, Kevin P. Marzo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44119 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
In-hospital SGLT2 inhibitor initiation, prescribing gaps, and 30-day all-cause readmission in heart failure with reduced ejection fraction: a US post-guideline cohort study Authors: Otabek Pulatov, Soo Young Kim, Zvi Grossman, Farhan Noor, Bilal Salam, Tahmid Khan, Akhila Matam, Shan Wang, Thomas Caraccio, Kevin P. Marzo Published: 2026 ABSTRACT BackgroundHeart failure accounts for more than one million US hospitalizations annually, with 30-day all-cause readmission approaching 25% and triggering CMS Hospital Readmissions Reduction Program penalties. The 2022 ACC/AHA/HFSA guideline and the 2023 ESC focused update elevated SGLT2 inhibitors to Class I therapy for heart failure with reduced ejection fraction (HFrEF) [1, 2]. The DAPA ACT HF–TIMI 68 prespecified meta-analysis demonstrated reductions in cardiovascular death or worsening heart failure (HR 0.71) and all-cause mortality (HR 0.57).Real-world prescribing patterns and 30-day readmission outcomes in the post-guideline US era are not well characterized. The relative contribution of clinical stability variables versus co-prescribed guideline-directed medical therapy (GDMT) to confounding has not been directly quantified in this setting.MethodsWe conducted a retrospective cohort study at four NYU Langone Health hospitals from January 2023 to January 2026. Adults with a primary heart failure discharge diagnosis were included.The prespecified primary analysis was in the HFrEF subgroup (LVEF ≤ 40%). The primary outcome was 30-day all-cause readmission. Stabilized inverse probability of treatment weighting (IPTW) was the primary adjustment, with overlap weighting (ATO) as sensitivity analysis.Hierarchical logistic regression decomposed the confounding contribution of clinical stability parameters relative to GDMT. The E-value assessed robustness to unmeasured confounding.ResultsAmong 438 patients, 122 (27.9%) received in-hospital SGLT2 inhibitor initiation. The HFrEF rate was 41.6%, a sixfold increase from 6.6% reported in INSIGHT-HF (2020–2021). Patients with prior heart failure hospitalization received SGLT2 inhibitors at 11.4% versus 29.7% in those without (p < 0.001). In HFrEF (n = 221), 30-day readmission was 12.1% versus 31.8% (crude OR 0.29, 95% CI 0.14–0.61). The primary IPTW estimate was OR 0.34 (95% CI 0.13–0.91, p = 0.032). Sensitivity analyses were directionally consistent. Clinical stability parameters contributed only 9.3% confounding attenuation; GDMT was the dominant confounder.ConclusionsIn a contemporary US post-guideline cohort, in-hospital SGLT2 inhibitor initiation reached 41.6% in HFrEF but remained low in patients with recent heart failure hospitalization. In-hospital SGLT2 inhibitor initiation was associated with lower 30-day all-cause readmission, though initiation was strongly bundled with discharge GDMT optimization and cannot be distinguished from a GDMT optimization effect with this study design. These findings should be considered hypothesis-generating. Because short-term safety events and post-discharge persistence were not systematically captured, these findings should not be interpreted as establishing the benefit-risk profile of inpatient SGLT2 inhibitor initiation. The prescribing gap in high-risk patients is an actionable quality-improvement target.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12872-026-06184-y. Introduction Heart failure accounts for more than one million hospitalizations annually in the United States, with 30-day readmission rates approaching 25% despite decades of quality-improvement effort [3]. The CMS Hospital Readmissions Reduction Program (HRRP), enacted in 2012, penalizes hospitals for excess heart failure readmissions. National rates have plateaued rather than declined [4]. This plateau persists despite four pillars of guideline-directed medical therapy (GDMT) now carrying Class I recommendations for heart failure with reduced ejection fraction (HFrEF) [1]. Sodium-glucose cotransporter 2 (SGLT2) inhibitors occupy a distinctive position among GDMT. They have a favorable initiation profile in the acute setting, with minimal blood pressure effects, fixed dosing, and natriuretic properties [5]. DAPA-HF and EMPEROR-Reduced established benefits in chronic HFrEF regardless of diabetes status [6, 7]. EMPULSE and SOLOIST-WHF demonstrated safety and efficacy when initiation occurs in or near hospitalization [8, 9]. The DAPA ACT HF–TIMI 68 trial showed a neutral 2-month primary outcome, but the prespecified three-trial meta-analysis demonstrated reductions in cardiovascular death or worsening heart failure (HR 0.71, 95% CI 0.54–0.93) and all-cause mortality (HR 0.57, 95% CI 0.41–0.80) [10]. The 2022 ACC/AHA/HFSA guideline elevated SGLT2 inhibitors to Class I therapy [1]. INSIGHT-HF reported a 6.6% in-hospital initiation rate during 2020–2021, before the guideline update [11]. Three gaps in the existing evidence base motivate this study. First, no completed clinical trial has used 30-day all-cause readmission — the HRRP penalty metric — as a primary endpoint. Second, prior observational studies have relied on administrative claims data lacking clinical parameters [12], or used propensity matching with few covariates and without GDMT adjustment [13]. The relative confounding contribution of clinical stability parameters versus GDMT in this setting has not been directly quantified. Third, and most importantly, the prescribing landscape has shifted considerably since these earlier studies. A contemporary US post-2022 guideline cohort captures a different prescribing environment — one with higher SGLT2 inhibitor uptake, evolved patient selection, and greater concurrent GDMT intensity — that earlier implementation analyses were not designed to capture. We conducted a retrospective cohort study using granular electronic health record data from a large US academic health system to address these gaps. The primary objective was to assess the association between in-hospital SGLT2 inhibitor initiation and 30-day all-cause readmission, with the prespecified primary analysis in HFrEF where biological rationale and guideline evidence are strongest. The methodological objective was to quantify the confounding contribution of clinical stability parameters absent from prior claims-based studies. Methods Study design and setting This was a retrospective cohort study at NYU Langone Health, a US academic health system with four acute-care hospitals: Tisch Hospital (Manhattan), Hospital—Long Island (Mineola), Hospital—Brooklyn, and Hospital—Suffolk. The Epic-based electronic health record provided vital signs, laboratory values, medications, and echocardiographic data unavailable in administrative claims. The study period was January 2023 through January 2026, capturing the post-2022 ACC/AHA/HFSA guideline era. The Institutional Review Board approved the study with waiver of informed consent (Protocol s25-00254). Reporting followed STROBE guidelines [14]. Study population We identified adults (≥ 18 years) with a primary heart failure discharge diagnosis (ICD-10-CM I50.x). Left ventricular ejection fraction (LVEF) was ascertained from transthoracic echocardiography during the index admission or within the prior 12 months. HFrEF was defined as LVEF ≤ 40%. Exclusion criteria were SGLT2 inhibitor use within 12 months before admission; type 1 diabetes mellitus; history of diabetic ketoacidosis; end-stage renal disease or chronic dialysis; in-hospital death; discharge to hospice facility; missing LVEF; and discharge disposition recorded as “Still a Patient.” Only the first qualifying admission was included for patients with multiple eligible admissions. The final analytic cohort comprised 438 patients (122 SGLT2 inhibitor recipients, 316 controls). Exposure SGLT2 inhibitor exposure was defined as in-hospital initiation with a discharge prescription. Among 122 recipients, 116 received empagliflozin and 7 received dapagliflozin (one patient received both sequentially). The predominant dose was 10 mg daily for both agents. Outcomes The primary outcome was 30-day all-cause readmission, defined as any unplanned inpatient admission within 30 days of discharge. Planned readmissions identified by scheduled admission type were excluded. All-cause readmission was selected because it aligns with the CMS HRRP penalty metric, avoids misclassification from inconsistent heart failure coding, and captures pleiotropic SGLT2 inhibitor effects across cardiac, renal, and metabolic pathways. Readmissions were ascertained through the NYU Langone EHR. Out-of-system readmissions were not captured. Secondary outcomes were 90-day all-cause readmission and 30-day all-cause mortality. Primary subgroup The HFrEF subgroup (LVEF ≤ 40%) was the prespecified primary analysis population. This designation was based on Class I guideline evidence [1], the strongest trial evidence base (DAPA-HF, EMPEROR-Reduced, DAPA ACT HF–TIMI 68) [6, 7, 10],